BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20303261)

  • 1. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
    Patel RR; Sengupta S; Kim HR; Klein-Szanto AJ; Pyle JR; Zhu F; Li T; Ross EA; Oseni S; Fargnoli J; Jordan VC
    Eur J Cancer; 2010 Jun; 46(9):1537-53. PubMed ID: 20303261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
    Ayers M; Fargnoli J; Lewin A; Wu Q; Platero JS
    Cancer Res; 2007 Jul; 67(14):6899-906. PubMed ID: 17638901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
    Bhide RS; Lombardo LJ; Hunt JT; Cai ZW; Barrish JC; Galbraith S; Jeyaseelan R; Mortillo S; Wautlet BS; Krishnan B; Kukral D; Malone H; Lewin AC; Henley BJ; Fargnoli J
    Mol Cancer Ther; 2010 Feb; 9(2):369-78. PubMed ID: 20103604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
    Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
    Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
    Lin HC; Huang YT; Yang YY; Lee PC; Hwang LH; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Liu RS
    J Gastroenterol Hepatol; 2014 May; 29(5):1073-82. PubMed ID: 24325631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivanib alaninate for cancer.
    Diaz-Padilla I; Siu LL
    Expert Opin Investig Drugs; 2011 Apr; 20(4):577-86. PubMed ID: 21391890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice.
    Chen J; Saggar JK; Corey P; Thompson LU
    Br J Nutr; 2011 Feb; 105(3):339-47. PubMed ID: 21138602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
    Jonker DJ; Rosen LS; Sawyer MB; de Braud F; Wilding G; Sweeney CJ; Jayson GC; McArthur GA; Rustin G; Goss G; Kantor J; Velasquez L; Syed S; Mokliatchouk O; Feltquate DM; Kollia G; Nuyten DSA; Galbraith S
    Ann Oncol; 2011 Jun; 22(6):1413-1419. PubMed ID: 21131369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
    Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
    Syed S; Clemens PL; Lathers D; Kollia G; Dhar A; Walters I; Masson E
    J Clin Pharmacol; 2012 Jun; 52(6):914-21. PubMed ID: 21659627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
    Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
    Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells.
    Garvin S; Nilsson UW; Dabrosin C
    Br J Cancer; 2005 Oct; 93(9):1005-10. PubMed ID: 16234819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
    Gong J; Gan J; Masson E; Syed S; Xia YQ; Williams D; Pursley J; Jemal M; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2012 Dec; 40(12):2374-80. PubMed ID: 22983304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
    Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.
    Fan P; Agboke FA; Cunliffe HE; Ramos P; Jordan VC
    Eur J Cancer; 2014 Nov; 50(16):2866-76. PubMed ID: 25204804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
    Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
    Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.